Eton Pharmaceuticals, Inc. ETON Uridine Triacetate — Payments To Acquire Marketing Rights
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Eton Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept eton:PaymentsToAcquireMarketingRights.
The source filing: Eton Pharmaceuticals, Inc.’s 10-K, filed March 19, 2026.
- Filed
- Mar 19, 2026, 4:15 PM EDT
- Fiscal year
- FY2026
- Accession
- 0001437749-26-009059
In January 2026, the Company entered into a licensing and supply agreement for the U.S. marketing rights for an ultra-rare disease metabolic product candidate. Under the terms of the licensing and supply agreement, the Company paid $1,000 upon execution of the agreement and will pay seller $1,000 upon approval of the Abbreviated New Drug Application and commercial launch. The Company will pay profit sharing of 30.0% on net sales of the product candidate.
Item 1A. Risk Factors
FAQ
- What is Eton Pharmaceuticals, Inc.'s uridine triacetate — payments to acquire marketing rights?
- Eton Pharmaceuticals, Inc. (ETON) reported uridine triacetate — payments to acquire marketing rights of $1M in Q1 2026.
- What does uridine triacetate — payments to acquire marketing rights mean?
- This metric represents the total cash outflows or contractual obligations incurred to secure the exclusive rights to market and distribute a specific pharmaceutical product. It reflects the upfront or milestone-based capital investment required to build the company's product portfolio. Monitoring these payments helps investors assess the cost of business development and the company's strategy for expanding its rare disease pipeline.
Ask your AI about Eton Pharmaceuticals, Inc.'s uridine triacetate — payments to acquire marketing rights.
Connect your AI assistant and compare it to peers, right in your chat.
